Repeated Muscle Injury as a Presumptive Trigger for Chronic Masticatory Muscle Pain by Dessem, Dean & Lovering, Richard M.
Hindawi Publishing Corporation
Pain Research and Treatment
Volume 2011, Article ID 647967, 13 pages
doi:10.1155/2011/647967
Review Article
Repeated Muscle Injuryasa PresumptiveTriggerfor
ChronicMasticatoryMuscle Pain
Dean Dessem1,2 and RichardM.Lovering2,3
1Department of Neural and Pain Sciences, University of Maryland, 650 West Baltimore Street, Baltimore, MD 21201, USA
2Graduate Program in Life Sciences, University of Maryland, 650 West Baltimore Street, Baltimore, MD 21201, USA
3Department of Orthopaedics, University of Maryland, 20 Penn Street, Baltimore, MD 21201, USA
Correspondence should be addressed to Dean Dessem, ddessem@umaryland.edu
Received 31 January 2011; Accepted 14 April 2011
Academic Editor: Cyril Rivat
Copyright © 2011 D. Dessem and R. M. Lovering. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
skeletalmuscles sustain a signiﬁcantlossof maximalcontractile force after injury, but terminally damaged ﬁbers can eventually be
replaced bythegrowthofnewmuscle(regeneration),withfull restorationofcontractileforceovertime.After asecondinjury, limb
muscles exhibit a smaller reduction in maximal force and reduced inﬂammation compared with that after the initial injury (i.e.,
repeated bout eﬀect).In contrast,masticatorymusclesexhibitdiminishedregeneration andpersistent ﬁbrosis,afterasingleinjury;
followinga second injury, plasma extravasationis greater than after a single injury and maximalforce is decreased more thanafter
theinitialinjury. Thus,masticatorymusclesdo notexhibita repeated bout eﬀect andare insteadincreasinglydamagedby repeated
injury. We propose that the impaired ability of masticatory muscles to regenerate contributes to chronic muscle pain by leading
to an accumulation of tissue damage, ﬁbrosis, and a persistent elevation and prolonged membrane translocation of nociceptive
channels such as P2X3 as well as enhanced expression of neuropeptides including CGRP within primary aﬀerent neurons. These
transformations prime primary aﬀerent neurons for enhanced responsiveness upon subsequent injury thus triggering and/or
exacerbating chronic muscle pain.
1.Introduction
Musculoskeletal pain is estimated to aﬄict 15% of the pop-
ulation, is one of the most frequent symptoms encountered
by primary care providers [1, 2], and comprises a substantial
portion of the total cost of illness [1–3]. Muscle pain is a
prominent component in many musculoskeletal disorders,
including low-back pain, tension-type headache, ﬁbromyal-
gia and whiplash [4–6]. In the craniofacial region, temporo-
mandibulardisorders(TMD)aﬀect4–12%ofthepopulation
(∼35 million in the United States), with masticatory muscle
pain being the most frequent (66%) patient complaint [7].
TMDs are often not restricted to the temporomandibular
joint, but frequently include pain and tenderness of the
masticatory muscles [4–6]d e s i g n a t e da sG r o u pIi nt h e
ResearchDiagnosticCriteriaforTMD[8].Itisestimatedthat
one-half of TMD cases are these masticatory myalgias [9].
Patients with TMD frequently also have ﬁbromyalgia [10–
12], a musculoskeletal disorder characterized by widespread
musculoskeletal pain and diﬀuse muscle tenderness [11].
Approximately 2–5% of the population meet the diagnostic
criteria for ﬁbromyalgia [13, 14]. The similarities of TMD
and ﬁbromyalgia have lead to speculation that these condi-
t i o n sm a yi n v o l v ec o m m o nm e c h a n i s m so fm u s c l ep a i nw i t h
diﬀerent durations [15, 16]. While little is known about the
mechanisms underlying muscle pain, available data indicate
that the mechanisms underlying muscle pain diﬀer from
those underlying cutaneous or visceral pain (for review see
[17, 18]).
In spite of the prevalence of muscle pain, current
therapies for muscle pain are often ineﬀective and can even
be dangerous [19]. For instance, NSAIDS and COX-2 drugs
are no more eﬀective than placebo in treating some types of
musclepainandhavesubstantialrisks[20–25].Weakopioids
(e.g., codeine, tramadol) do not alleviate pain produced
by muscle injury [23, 26]. More powerful opioids such as
hydrocodone, morphine, and oxycodone can reduce chronic
pain, but have many deleterious eﬀects [27–29]. Thus it is2 Pain Research and Treatment
important to understand the mechanisms of muscle pain
in order to develop new, eﬀective therapeutic strategies for
muscle pain.
Pain resulting from muscle disorders can be persistent,
although the mechanisms by which this chronic pain
becomes established are not understood. Patients with
TMD and ﬁbromyalgia exhibit altered central nociceptive
processing [30–33], which is hypothesized to be generated
by a peripheral trigger [34]. Nociceptive input from muscle
aﬀerents is particularly potent at generating CNS wind-up
[35]. Recent muscle pain studies support the involvement of
peripheral stimuli in chronic muscle pain by demonstrating
that enhanced central pain processing in ﬁbromyalgia is
maintained bymuscleaﬀerentinput[36,37].Wepredictthat
comparable processes exist in muscle-based TMDs, given
the similar characteristics of ﬁbromyalgia and muscle-based
TMDs [15, 16]. In this communication, we explore the
potential for muscle injury to contribute to the triggering
and/or maintenance of chronic pain.
2.TypicalExperimentalMethodsof
ProducingMusclePainDoNot Accurately
Model Muscle Pain
In spite of its prevalence, currently there are no widely
accepted models of muscle pain, and most methods used
to investigate muscle pain do not accurately reproduce the
features of pain reported in humans suﬀering from muscle
pain. For instance, injection of exogenous substances such
as complete Freund’s adjuvant (CFA) [38–40] has been used
to evokeinﬂammatory muscle pain. However, CFA produces
a massive inﬂammatory response with large intramuscular
vacuoles and enormous inﬂammatory cell inﬁltration [38],
characteristicsthatdiﬀersodramaticallyfromthosereported
in muscle pain patients [41]t h a ta d j u v a n ti n j e c t i o nh a s
only very limited relevance for studies of muscle pain.
While injection ofhypertonic saline producessensations that
mimic muscle pain [42, 43], hypertonic saline activates both
musclenociceptors[44,45] and nonnociceptors [46, 47]an d
does not alter muscle lactate or PGE2 as reported in muscle
pain [45]. Acidic saline injected into limb muscles activates
some muscle aﬀerents [47] and produces hyperalgesia [48–
50]. AlthoughASIC3 (acid-sensing ion channels) are present
on craniofacial muscle aﬀerents [51, 52], injection of acidic
saline into the masseter does not produce hyperalgesia or
alter calcitonin gene-related peptide (CGRP) and substance
P expression [51]. Acid saline, therefore, is a valuable model
for limb, but not craniofacial muscle pain. Injection of the
polysaccharide carrageenan activates ﬁne muscle aﬀerents
and produces hyperalgesia [53–55], but does not elevate
intramuscular TNF-α [23]. Since TNF-α is elevated in TMD
and ﬁbromyalgia [56–58], carrageenan is not an accurate
model for TMD and ﬁbromyalgia. Mustard oil and capsaicin
both inﬂame tissue including muscle [59–64]. Mustard oil
acts via TRP (transient receptor potential channel) A1
channels on a subset of unmyelinated ﬁbers [65]w h i l e
capsaicin acts via TRPV1 channels on a subset of unmyeli-
nated muscle aﬀerents [66]. Since algogens do not activate
thinly myelinated muscle aﬀerents, they do not activate the
spectrum of aﬀerent types that participate in muscle pain
[67–69]. Endogenous substances have also been injected
into muscles. Serotonin, bradykinin, ATP, TNF-α,a n dN G F
activate a subpopulation of muscle aﬀerents and produce
pain [47, 52, 70–77]. Single substances (5-HT, bradykinin,
etc.) interact with subsets of nociceptors providing insight
into speciﬁc aspects of nociception; however, they cannot
simulate muscle pain that involves multiple nociceptive
channels and aﬀerent types. Even if multiple algogens
are used [73, 78], the environment at nerve terminals
during pain cannot be reproduced due to diﬀerences in
spatial application of the algogen, diﬀusion, and the fact
that diﬀerent mediators do not appear simultaneously in
inﬂammation. Forthesereasons, we concentrateinthiscom-
munication on data derived from eccentric (lengthening)
muscle contractions, a noninvasive, physiologically relevant
in vivo model of producing muscle pain and inﬂammation.
This model of muscle strain injury incorporates movement
and contraction, fundamental properties of muscle [79, 80].
When an activated muscle is forced to lengthen because
the externalload exceedsthe tensiongeneratedbythe muscle
contraction, this is termed a lengthening ‘eccentric’ contrac-
tion. Although eccentric contractions require less energy, the
force generated during a maximal eccentric contraction is
about double the force developed during a maximal isomet-
ric contraction; therefore eccentric contractions are more
likely to produce damage than either isometric or concentric
(shortening) contractions. Using an animal model, forceful
eccentric muscle contraction uniquely disrupts selected
myoﬁbers [79, 81], comparable to the selective myoﬁber
damage in humans after eccentric exercise [82]. As few as
12 unaccustomed voluntary eccentric muscle contractions
can produce muscle pain often referred to as delayed onset
muscle soreness (DOMS) [83]. Furthermore, inﬂammation
evokedby musclecontractiontypically developsmore slowly
than the pulsatile inﬂammation produced by injection of
algogens such as CFA, which evoke changes in neuropeptide
mRNA within 30min [38]. Eccentric muscle contractions
can be produced in the laboratory setting by manually
lengthening a muscle during electrical stimulation [84,
85]. Only a few contractions are needed to induce readily
detectable muscle inﬂammation [84, 86]. Both voluntary
and stimulus-induced eccentric muscle contraction as well
as rapid muscle stretching damage a subpopulation of
myoﬁbers [81, 82, 87, 88], produce muscle pain and soreness
[45, 85], evoke myonecrosis, induce inﬂammatory inﬁltra-
tion, elevate inﬂammatory proteins [81, 84, 89, 90], decrease
muscle force and range of motion (for review [91]), and
activate genes associated with muscle repair and apoptosis
[92]. Intramuscular calcitonin gene related peptide (CGRP)
and vascular endothelial growth factor (VEGF), a proangio-
genic cytokine which increases after exercise [93–95], also
increase after eccentric muscle contraction [81]. While in
thispaperwepresentdataderivedfromeccentriccontraction
produced by muscle lengthening following supramaximal
muscle contraction, comparable, but smaller eﬀects are
observed following submaximal eccentric contractions and
behaviors such as downhill running [90, 96].Pain Research and Treatment 3
3.InjuryEvokesDifferentialEffectsin
MusclesfromVariousBodyRegions
Repairandregeneration inhindlimb musclefollowing injury
involves activation of satellite cells within 24–48 hours
[97]. These mononuclear cells are situated outside the
sarcolemma, but inside the basement membrane of each
muscle ﬁber. They are normally quiescent, however they are
thought to become active with stimulation (e.g., injury).
Under appropriate conditions, satellite cells develop into
myoblasts, which fuse to form myotubes [98]. Myotubes can
then repair, or even replace, damaged muscle ﬁbers. It is
generallyhypothesized thatsatellite cells,afterseveralrounds
of proliferation, are a determinant factor in the functional
recovery of muscle. Within 7–14 days following injury,
myoﬁbers are approaching normal size [99]a n dm y o ﬁ b e r s
return to normal by 24 days [100]. Evidence indicates
that the response to eccentric contraction diﬀers between
hindlimb and forelimb muscles. Blood creatine kinase levels
and muscle soreness are reported to be greater following
muscle damage to forelimb compared to hindlimb muscles
[101]. Recovery of function after injury is also reported to
be slower in forelimb versus hindlimb muscles [101]. In
fact, when direct comparisons are made using similar indices
of muscle damage, creatine kinase levels are greater after
forelimb eccentric contraction and muscle recovery is longer
for forelimb muscles [102].
Masticatory muscle responds very diﬀerently to injury
than hindlimb muscle. Twelve days following muscle injury
produced by a single crush or freezing injury, large areas
of muscle exhibit minimal evidence of muscle regeneration
[98]. Following a similar injury, hindlimb muscle shows
centrally nucleated ﬁbers (CNFs), indicative of regenerating
muscle. At 19–21 days following injury, masseter muscle
regeneration is still impaired and the masseter muscle
exhibits extensive interstitial connective tissue. Even 45 days
following asingle injury, regenerationofthemasseter muscle
is less extensive than observed in hindlimb muscle 12 days
after injury [98].
We have observed comparable ﬁndings after muscle
injury produced by a single bout of eccentric muscle
contractions [81]. Adult, male Sprague Dawley rats were
used for all experiments. Animals received humane care
in compliance with the G u i d ef o rt h eC a r ea n dU s eo f
Laboratory Animals (NIH publication no. 86–23, revised
1985) and the Use Committee and the Committee for
Research and Ethical Issues of the IASP. All laboratory
procedures were reviewed and approved by the University of
Maryland Animal Care and Use Committee and every eﬀort
was made to minimize any suﬀering. We ﬁrst anesthetized
t h es k i no v e r l y i n gt h em a s s e t e rm u s c l eb ya p p l y i n ga
topical anesthetic (2.5% lidocaine, 2.5% prilocaine). We
used a combination of lidocaine and procaine because this
eutectic mixture has been shown to produce more eﬀective
cutaneous anesthesia in humans than either substance alone
[103]. After two hours, when topical anesthesia was well
established, rats were anesthetized with isoﬂurane. We have
previously shown that lidocaine/prilocaine cream produces
cutaneous anesthesia in the rat facial skin at this time
[104]. A rod coupled to a stepping motor and potentiometer
was then positioned in the diastema of the mandible. To
produce eccentric contraction of the masseter muscle, we
used an established in vivo model previously described for
the hindlimb [79, 80, 105]. The masseter was contracted
by electrical stimulation (1s trains, 100Hz, 0.3ms pulse at
0.3Hz) using surface electrodes. Stimulation current was
adjusted (5–12mA) to produce a supramaximal muscle
contraction. Neurogenicplasma extravasation was prevented
by anesthetising the skin overlying the muscle [81]a n d
using a high-frequency stimulation regime, which does
not activate group III and IV masseter muscle aﬀerent
axons [106]. Eccentric muscle contraction was produced
by displacing the mandible 25 degrees of jaw opening at
ar a t eo f0 . 6 ◦/ms 150 milliseconds into a maximal muscle
contraction. Mandibular displacement was produced using
a stepping motor (1.8◦/step NMB Technologies, Chatsworth,
CA) controlled by a custom LabVIEW program (LabVIEW,
version 8.5 National Instruments, Austin, TX). Muscle
torque was measured using a torque sensor (model QWLC-
8 M Sensotec, Columbus OH) and ampliﬁer (model DV-
05, Sensotec). Angular displacement of the mandible was
monitored with a potentiometer. Displacement, angular
position, and torque were synchronized using a custom
LabVIEW program. Signals were sampled at 2KHz using
a 16-bit analog-to-digital converter (PCI-6221, National
Instruments). The eccentric muscle contraction regime
consisted of 5 sets of 15 eccentric muscle contractions (75
total contractions) with a ﬁve-minute rest between sets.
Muscle regeneration was not evident 32 days after one
bout of eccentric contraction of the masseter muscle [107]
and considerable ﬁbrosis was present (Figure 1). These
characteristics correspond to the impaired regeneration and
extensive ﬁbrosis evident for at least 45 days after crush or
freeze injury to the masseter muscle [98]. In contrast to
the masseter muscle, hindlimb muscles such as the tibialis
anterior regenerate in 7–12 days after crush or freeze injury
[98] and 5–14 days after eccentric muscle contraction [105,
108].
We operationally deﬁned muscle injury as a loss in the
ability of the muscle to produce force. Torque of a muscle
is represented by the equation T = F ∗ d,w h e r eT is
torque, F is muscle force, and d is the moment arm of the
muscle. Because we use a maximal tetanic contraction and
we measured torque at a ﬁxed position, our measure of
torque ultimately reﬂects muscle force. Maximal contractile
force is a strong indicator of the overall status of a muscle
[109] and a reliable indicator of injury [110, 111]. Therefore,
we investigated loss of maximal torque following injury in
masticatory and hindlimb muscles. A variety of contraction
schemes were tested,and wefound that 60masseter eccentric
contractions (0.6◦/ms) produce a 43% reduction in maximal
torque measured at resting length (L0)1 0m i n u t e sa f t e r
contraction (Figure 2,a r r o wn = 6 rats). For the tibialis
anterior muscle (n = 25), 150 eccentric contractions
producedinananalogousmannerresultedina41%deﬁcitin
maximal torque (Figure 2,a s t e r i s k[ 105]). Thus, to produce
a comparable loss of isometric force following a single bout
of eccentric muscle contraction, less than one-half as many4 Pain Research and Treatment
(a) (b)
Figure 1:PhotomicrographofthemassetermusclestainedwithH&E.(a)Naivemassetermuscle.(b)Massetermuscle12daysaftereccentric
muscle contraction. Arrows indicate regions of ﬁbrosis. Scale bar = 100μm.
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Figure2:Maximalisometrictorqueproduced beforeandatvarious
times after eccentric muscle contraction. Solid line is masseter
muscle and dashed line is tibialis anterior muscle. Note equivalent
loss of force for Masseter and tibialis anterior at day 0 after
eccentric contraction. Asterisks denote signiﬁcant reductions from
initialmaximaltorque. masseter= 60eccentric contractions,tibialis
anterior = 150 eccentric contractions, masseter n = 6, and tibialis
anterior n = 25.
eccentric contractions of the masseter muscle were needed
than for the tibialis anterior muscle (Figure 2). These data
suggest that the loss of contractile force in the masseter
after injury evoked by a single bout of eccentric muscle
contractions is greater than in hindlimb muscles. Much less
information is available on the eﬀects of injury on muscles
from other parts of the body such as the back and neck
which may have profound signiﬁcance for musculoskeletal
pain disorders. It will be particularly important for future
studies to determine the eﬀects and functional signiﬁcance
of injury on muscles from other regions of the body, such as
thebackand neck,which may haveprofound signiﬁcance for
musculoskeletal pain disorders.
4.MasticatoryMusclesDo Not Exhibita
RepeatedBoutEffect
In limb muscles, lengthening contractions are associated
with injury, but they can also provide signiﬁcant protection
against future injury. Compared to the ﬁrst bout, a second
bout of lengthening contractions in hindlimb and forelimb
muscles is associated with a decreased loss of contractile
force, less soreness, and a reduction in the amount of muscle
proteins in the blood. However, little is known about the
conditions that result in the protective adaptation [108, 112–
117]. This adaptive eﬀect is often referred to as the repeated
bout eﬀect (RBE) and has been demonstrated in both
animals and humans (for review see [118]). While a number
of mechanisms have been proposed to underlie the RBE
includingneuronal,cellular,andmechanical adaptations,the
processes involved in the RBE are still not well established.
Neuronal mechanisms, such as changes in motor unit
recruitment, have been proposed. Although there is some
evidence for changes in motor unit recruitment following
injury, theRBEcan beevokedbyelectricalstimulation [113],
indicating that changes in motor unit recruitment alone are
not suﬃcient to account for the repeated bout eﬀect.
TheRBEhasalsobeenattributedtocellularmechanisms,
including change in the number of sarcomeres, excitation-
contraction coupling, and/or inﬂammation. An increase in
the number of sarcomeres has been reported following
eccentric exercise [119–121]. However, the RBE can also
be demonstrated following a minimal stimulus, such as a
few eccentric contractions, or passive stretching, a stimulus
that may be insuﬃcient to evoke sarcomere remodeling
[118]. While excitation-contraction coupling can be dis-
rupted immediately following eccentric contraction [122],
it does not correspond to the timing of loss of strength in
humans several days following a repeated bout of eccentric
contraction [112]. Inﬂammation typically occurs following
eccentric musclecontraction [86, 90],and this inﬂammatory
response is reduced following a subsequent bout of eccentric
hindlimb or forelimb muscle contraction [114, 123]. It has
been proposed that inﬂammation may help to provide a
protective function from damage after subsequent bouts ofPain Research and Treatment 5
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Figure 3: Plasmaextravasationafter oneandtwo bouts ofeccentric
contraction of the masseter muscle. Note the increased plasma
extravasation after two bouts of eccentric contraction. Asterisk
denotes signiﬁcant diﬀerence from na¨ ıve and number sign denotes
signiﬁcantdiﬀerence from 1 bout.
eccentric muscle contraction [123, 124]. Myoﬁber damage
produced by a bout of eccentric muscle contractions is
reduced after subsequent bouts [125]. Thus, it is diﬃcult to
determine if the reduced inﬂammation that occurs following
a repeated bout of contractions is a primary process, or
reduced due to diminished tissue injury. However, it has
been shown that passive stretching and concentric muscle
contraction, processes that do not produce overt tissue
damage evident at the light microscopical level, can evoke a
smallrepeatedbouteﬀect[126].Alterationinthemechanical
properties of muscle including muscle stiﬀness and altered
expression of cytoskeletal proteins have also been postulated
to contribute to the RBE. While passive muscle stiﬀness
increases following eccentric exercise [127], it is unclear that
this increases the susceptibility of the muscle to injury [128].
Thus while several of these mechanisms may contribute to
the RBE, the precise mechanisms of the repeated bout eﬀect
remain elusive.
Little is known about the eﬀects of repeated injury on
craniofacial muscle, therefore we have begun to examine
repeated injury of the masseter muscle. Craniofacial muscle
has distinct origins and developmental regulatory mecha-
n is m sf r omth a toflim bm us cle.T h em a s s et erisderi v edf r om
the ﬁrst pharyngeal (branchial) arch and has been shown
to respond diﬀerently to muscle injury [98]. The eﬀect of
impaired regeneration and ﬁbrosis of the masseter muscle
after repeated injury was initially investigated by examining
plasma extravasation deﬁned here as (wet muscle weight −
dry muscle weight/wet muscle weight) × 100, as an index
of muscle edema [81]. Muscle edema signiﬁcantly increased
not only after one bout of eccentric contraction compared
to naive (Figure 3 asterisk) but also after two bouts of
contraction spaced 12 days apart (Figure 3 number sign).
Note that muscle edema increased signiﬁcantly after two
bout compared to one bout of contraction indicating a lack
of repeated bout eﬀect (naive n = 4, 1 bout n = 4, 2 bouts
0
20
40
60
80
100
I
n
i
t
i
a
l
D
a
y
0
D
a
y
4
D
a
y
7
D
a
y
1
2
D
a
y
0
–
2
n
d
b
o
u
t
D
a
y
4
D
a
y
1
2
D
a
y
3
6
∗
M
a
x
i
m
a
l
i
s
o
m
e
t
r
i
c
t
o
r
q
u
e
o
f
n
o
n
i
n
j
u
r
e
d
m
u
s
c
l
e
(
%
)
Figure 4: Eﬀect of repeated masseter muscle injury on maximal
isometric torque. Asterisk denotes signiﬁcant diﬀerence from
maximal torque after a single bout of eccentric contraction (day 0
initial bout).
n = 6, P<.025 for 2 bouts versus 1 bout and .049 for 1
bout versusnaive, ANOVAfollowed by Holm-Sidakmethod,
Figure 3). Mechanical hyperalgesia was also measured by
determining the threshold for a head withdrawal reﬂex
[81]. Animals were initially habituated to stand unrestrained
on their hindpaws and lean on the tester’s hand covered
with a leather glove. Mechanical thresholds were then
determined by probing the masseter muscle through the
facial skin using a rigid von Frey ﬁlament coupled with a
force transducer with a ﬁxed contact area (Electrovonfrey,
model no 2290, IITC Inc). The force needed to produce a
withdrawal of the head was recorded following ﬁve stimulus
presentations at one minute intervals. The mean values of
the ﬁve readings was used for analysis. Using this method,
mechanical hyperalgesia wasfound tobemore profoundand
persisted for at least 7–14 days longer after multiple bouts
of eccentric contraction of the masseter muscle than one
bout (ANOVA, P<.05, n = 7). Taken together, these data
contrast strongly with data derived from hindlimb muscles,
which show a RBE in regards to inﬂammation and muscle
soreness [112, 113, 129]. We also examined the eﬀects of
two bouts of eccentric muscle contraction spaced 12 days
apart on masseter contractile function by measuring torque
in 7 male rats. After a second bout of eccentric contraction,
masseter maximal torque decreased by 79% compared to
the initial maximal torque at day 0, and decreased by an
additional 60% compared to maximal torque immediately
prior to the second bout of eccentric contractions (Figure 4).
These data show that a second bout of eccentric contractions
of the masseter muscle further reduces muscle force (Mann-
Whitney rank sum test, n = 7 animals per group, P=.026)
in contrast to the tibialis anterior muscle in which a second
bout of eccentric muscle contraction results in very little
or no further reduction in muscle force (i.e., repeated bout6 Pain Research and Treatment
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Reduced hyperalgesia
Increased inﬂammation
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Figure 5: Diagrammatic representation of the response of masticatory versus limb muscle to repeated injury.
eﬀect) [108, 113]. Thus, the masseter muscle not only lacks
a repeated bout eﬀect, but instead sustains increased damage
uponrepeated boutsofmuscleinjury (Figure5).We propose
this diﬀerence evokesmechanisms that contribute to chronic
craniofacial muscle pain.
5.Synthesisofthe RoleofMuscleInjuryin
ChronicMusclePainIncludingPotential
TherapeuticTargets
In this communication we show that repeated bouts of
injury to masticatory musclesdo not evokethe adaptive RBE
presentinlimbmuscles,butrathercompoundmuscleinjury.
Patients with TMD and ﬁbromyalgia exhibit altered central
nociceptive processing [30–33, 37], which is most likely
initially triggered from a peripheral source [34]. Nociceptive
input from muscle aﬀerent neurons is particularly potent at
generating central nervous system wind-up [35]. One poten-
tial source formuscle injury is oral parafunctional behaviors.
Evidence shows that oral parafunctional behaviors that
increase muscle tension are good predictors of orofacial pain
levels in patients with TMD [130, 131]. It is also known that
experimental bruxism produces muscle soreness, described
as moderate muscle pain that is exacerbated by movement
[132, 133]. Horizontal jaw movement at 50% maximum
voluntary contraction for 5min, or jaw protrusion and
retrusion under load, also produces delayed jaw muscle pain
[134]. Finally, eccentric, but not concentric, contraction
of the masseter muscle lowers the masseter pressure pain
threshold [135, 136], which is consistent with the greater
myoﬁber damage produced by eccentric contractions [137].
Since parafunctional behaviors can occur for prolonged
periods, we propose that the impaired ability of masticatory
muscles to regenerate results in neuronal transformations.
This in turn chronically enhances the responsiveness of
muscle primary aﬀerent neurons to subsequent injury and
thus serves as a source to initiate and/or exacerbate chronic
muscle pain.
Nerve growth factor (NGF) is a homodimeric protein
that binds to TrkA and p75 receptors [138, 139]a n di s
implicated in mechanical and heat hyperalgesia [140–143].
Severalﬁndings establish arolefor NGFinperipheralmuscle
pain mechanisms. First, NGF levels in the masseter muscle
of patients with TMD are negatively correlated with pressure
pain threshold and positively correlated with descriptors of
pain [144]. Levels of NGF are also elevated in inﬂamed
muscle following injury including injury evokedby eccentric
muscle contraction [145–147]. While other studies implicate
N G Fi nm u s c l ep a i n[ 77, 148, 149], high concentrations
of NGF were used. Several sources for intramuscular NGF
exist. Adult myoﬁbers do not produce NGF [150], although
developing and dystrophic myoﬁbers can [150, 151]. Other
potential sources for NGF include keratinocytes [152],
ﬁbroblasts [153], and mast cells [154–156]. NGF is known
to upregulate many nociceptive channels and neuropeptides
implicated in muscle pain [157–161], and, therefore, we
propose that NGF is not only involved in acute muscle
pain, but plays an instrumental role in chronic muscle
pain by sustained modulation of nociceptive channel and
neuropeptide expression. Among these, we expect that
P2X3 and CGRP are particularly important for deep tissue
craniofacial pain.
P2X receptors comprise a family of ionotropic receptors
which are activated by ATP (for review [162, 163]). In
muscle, injection of ATP elicits pain [73]a n da c t i v a t e s
muscle nociceptors [164]. Nonspeciﬁc P2X antagonists also
reduce nocifensive behavior following muscle pain [165].
One member of the P2X family, the P2X3 receptor, is
speciﬁcally implicated in nociception [166]. Since a much
higher percentage of craniofacial muscle aﬀerent neurons
express P2X3 than limb muscle aﬀerent neurons [167], P2X3
is particularly implicated in craniofacial deep tissue pain.
P2X3 receptors are present on masseter muscle aﬀerent
neurons [168] and rapidly desensitizing currents character-
istic of P2X3 receptors can be activated in a subpopulation
of masseter muscle aﬀerents by applying ATP [52]. P2X3
immunopositive muscle aﬀerent neurons are increased 15
days following repetitive muscle contraction and rapid
stretching [81]. Thus, physiologically relevant stimuli upreg-
ulate P2X3 in primary muscleaﬀerentneuronsfor prolonged
periodsoftime.OnepotentialsourceofATPtoactivateP2X3
receptors is ATP released from the cytosol of damaged cells.
In coculture systems, action potentials and inward currents
are evokedin nociceptorswhen nearby cellsare mechanically
damaged, and these responses are demonstrated to bePain Research and Treatment 7
mediated by ATP [169]. In muscle, the concentration of
ATP within myoﬁbers is approximately 10mM [170], a
concentration that readily activates muscle primary aﬀerent
neurons in vivo [164], demonstrating that suﬃcient ATP is
presentwithin myoﬁbers toactivate muscleaﬀerentneurons.
Since eccentric muscle contraction mechanically damages
myoﬁbers and disrupts their membrane [81], we propose
that ATP is released from damaged myoﬁbers following
muscle injury and activates P2X3 receptors on muscle
nociceptors.
Considerable evidence implicates the neuropeptide, cal-
citonin gene-related peptide (CGRP) in nociception and
inﬂammation [171–175]. CGRP is a 37 amino acid neu-
ropeptidesynthesizedinprimaryaﬀerentneurons.CGRPisa
potentvasodilatorofbloodvessels[171,176]includingthose
in muscles [176], and mediates neurogenic inﬂammation
[177]. CGRP has been implicated speciﬁcally in nociceptive
mechanisms from deep tissues [178], including muscle [54]
and intramuscular CGRP is signiﬁcantly increased following
muscle injury evoked by eccentric muscle contractions [94].
Seventy-ﬁve percent of masseter P2X3 muscle aﬀerents colo-
calize CGRP [168]. We predict that this extensive colocaliza-
tion indicates greater interaction between CGRP and P2X3
in trigeminal, compared to dorsal root ganglion neurons,
where neuropeptides and P2X3 are segregated [179, 180].
NGF not only upregulates CGRP [181], but also P2X3 [157,
159, 182]. We propose that increased intramuscular NGF
following myoﬁberinjury andmuscleinﬂammation notonly
upregulates CGRP, but also increases P2X3 expression in
muscle primary aﬀerent neurons priming the responsiveness
of these neurons upon subsequent injury.
Additional factors to consider are that stress and auto-
nomic dysfunction are correlated with some muscle pain
disorders [183–187]. When stress is combined with eccentric
contractions of hindlimb muscles, allodynia persists for up
to 35 days and becomes bilateral [188]. This ﬁnding demon-
strates that muscle injury can evoke long-lasting neuronal
plasticity. Thus, we predict that acute muscle injury, partic-
ularly when combined with stress, can evoke central nervous
system changes after which pain can become independent
of peripheral drive, and that intermittent muscle injury
exacerbates pain even after central pain transformations
have occurred. Little is known about potential interactions
between muscle injury, autonomic dysfunction, and the
developmentofchronicmusclepain,making itanimportant
area for future research.
We hypothesize that peripheral mechanisms involving
primary aﬀerent neurons from deep tissues are instrumental
in the development of central nervous system transforma-
tions, such as central sensitization that occurs in muscle-
based TMDs and ﬁbromyalgia [30–32, 189]. Thus, agents
capable of reducing primary aﬀerent drive evoked by muscle
inﬂammation have potential as acute therapeutics and
as modulators of long-term nociceptive phenomena. We
propose that increased intramuscular NGF after muscle
injury plays a critical role in chronic pain by persistently
upregulating P2X3 and CGRP in muscle primary aﬀerent
neurons. Although selective P2X3 antagonists exist [190],
rather than directly targeting P2X3, a potentially more
powerful approach is to concentrate on CGRP antagonists
and NGF biologics (for review [191, 192]), because these
agents have the potential to decrease both neurogenic
inﬂammation andP2X3 upregulation.We predictthatCGRP
antagonists will not only reduce vasodilatation and CGRP
synthesis and release, but that they will also attenuate the
upregulation of P2X3 receptors, reducing the activation of
muscle nociceptorsby ATP. We also anticipate that anti-NGF
antibodies will have multiple antinociceptive actions. These
include, but are not limited to, blocking NGF-mediated
upregulation of CGRP and reducing the upregulation of
P2X3 due to CGRP.
6.Conclusions
In this communication we have described diﬀerences in the
response to injury of masticatory muscle versus hindlimb
muscle. We also included new evidence that masticatory
m u s c l e sd on o ta d a p tt or e p e a t e di n j u r ya so c c u r si n
hindlimb muscle(i.e.,masticatory musclesdonotexhibitthe
repeated bout eﬀect). We propose that acute bouts of injury,
as occurs during oral parafunctions, increase intramuscular
nerve growth factor evoking a persistent upregulation of
nociceptive receptors and neuropeptides. This mechanism
primes primary aﬀerent neurons for enhanced responsive-
ness upon subsequent injury and serves to trigger and/or
exacerbate chronic muscle pain.
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